This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rigas, J. R. Search for Related Content PubMed PubMed Citation Articles by Rigas, J. R.

Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA

Correspondence: James R. Rigas, M.D., Comprehensive Thoracic Oncology Program, Norris Cotton Cancer Center, Dartmouth Medical School, One Medical Center Drive, Lebanon, New Hampshire 03756, USA. Telephone: 603-650-6344; Fax: 603-650-0536; e-mail: james.r.rigas{at}dartmouth.edu

Platinum-based chemotherapy is the treatment of choice for patients with non-small cell lung cancer (NSCLC). As a result of their single-agent activities and synergistic effects, taxane-platinum combinations are often used as first-line therapy for this disease. Four large, multicenter, randomized phase III clinical trials (the TAX 326 trial, the Southwest Oncology Group 9509 trial, the Italian Lung Cancer Project, and the Eastern Cooperative Oncology Group 1594 trial) have compared taxane-platinum combinations (docetaxel and paclitaxel) with other platinum combinations (vinorelbine and gemcitabine) in chemotherapy-naïve patients with good performance status scores and advanced disease. The end points for these large randomized clinical trials were survival, response rate, adverse events, and quality of life (QOL). Of the taxane-platinum combinations tested, docetaxel-cisplatin was the only platinum combination to yield survival and response rates superior to another platinum combination. In adverse event terms, the taxane-platinum combination of paclitaxel-carboplatin demonstrated less grade 3 or 4 neutropenia and lower rates of febrile neutropenia than other taxane-platinum combinations but higher rates of irreversible grade 3 or 4 peripheral neuropathy than any of the other taxane-platinum combinations. Additional differences emerged when QOL data were evaluated. The docetaxel-platinum combination demonstrated broad QOL benefits for patients receiving this combination, and this benefit was not observed with the other platinum or taxane-platinum combinations. As our use of these taxane-platinum combinations expands, these differences in survival, response rate, adverse events, and QOL will permit us to better balance our treatment goals for all patients with all stages of NSCLC.

Key Words. Chemotherapy • Docetaxel • Paclitaxel • Doublets • Non-small cell lung cancer

This article has been cited by other articles:

				M. Forster, S. Kaye, A. Oza, I. Sklenar, A. Johri, W. Cheung, S. Zaknoen, and M. Gore A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4178 - 4184. [Abstract] [Full Text] [PDF]

				P.-H. Tseng, Y.-C. Wang, S.-C. Weng, J.-R. Weng, C.-S. Chen, R. W. Brueggemeier, C. L. Shapiro, C.-Y. Chen, S. E. Dunn, M. Pollak, et al. Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor Mol. Pharmacol., November 1, 2006; 70(5): 1534 - 1541. [Abstract] [Full Text] [PDF]

				B. Moy and P. E. Goss Lapatinib: Current Status and Future Directions in Breast Cancer Oncologist, November 1, 2006; 11(10): 1047 - 1057. [Abstract] [Full Text] [PDF]

				T. Mijatovic, A. Op De Beeck, E. Van Quaquebeke, J. Dewelle, F. Darro, Y. de Launoit, and R. Kiss The cardenolide UNBS1450 is able to deactivate nuclear factor {kappa}B-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 391 - 399. [Abstract] [Full Text] [PDF]